Related references
Note: Only part of the references are listed.Mutation-Specific and Common Phosphotyrosine Signatures of KRAS G12D and G13D Alleles
Raiha Tahir et al.
JOURNAL OF PROTEOME RESEARCH (2021)
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition
Marco H. Hofmann et al.
CANCER DISCOVERY (2021)
Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer
Raffaela Santoro et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Meagan B. Ryan et al.
CLINICAL CANCER RESEARCH (2020)
The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill Hallin et al.
CANCER DISCOVERY (2020)
STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype
Carminia M. Della Corte et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
Jenny Y. Xue et al.
NATURE (2020)
Integration of multiple biological contexts reveals principles of synthetic lethality that affect reproducibility
Angel A. Ku et al.
NATURE COMMUNICATIONS (2020)
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
Vito Amodio et al.
CANCER DISCOVERY (2020)
Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer
Valeria Merz et al.
CLINICAL CANCER RESEARCH (2020)
PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer
Xiao Chen et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2020)
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Targeting Metalloenzymes for Therapeutic Intervention
Allie Y. Chen et al.
CHEMICAL REVIEWS (2019)
Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma
Kimmie Ng et al.
INVESTIGATIONAL NEW DRUGS (2019)
KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer
Wenting Liao et al.
CANCER CELL (2019)
Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
Arnaud Jeanson et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction
Roman C. Hillig et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
J. Mazieres et al.
ANNALS OF ONCOLOGY (2019)
Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study.
Tae Won Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer
Jessica M. Konen et al.
CANCERS (2019)
Drugging an undruggable pocket on KRAS
Dirk Kessler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer
Miriam Molina-Arcas et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
A view on drug resistance in cancer
Neil Vasan et al.
NATURE (2019)
KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
Sandra Misale et al.
CLINICAL CANCER RESEARCH (2019)
Intratumor heterogeneity and tissue distribution of KRAS mutation in non-small cell lung cancer: implications for detection of mutated KRAS oncogene in exhaled breath condensate
Jacek Kordiak et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling
Zhan Yao et al.
NATURE MEDICINE (2019)
Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer
Shunsuke Kitapma et al.
CANCER DISCOVERY (2019)
Kras and Tumor Immunity: Friend or Foe?
Jane Cullis et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
Efforts to Develop KRAS Inhibitors
Matthew Holderfield
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers
Andrew J. Aguirre et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers
Brian R. Untch et al.
CANCER RESEARCH (2018)
Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer
Eric Van Cutsem et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Daniele V. F. Tauriello et al.
NATURE (2018)
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
Ferdinandos Skoulidis et al.
CANCER DISCOVERY (2018)
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma A Systematic Review and Meta-analysis
Chee Khoon Lee et al.
JAMA ONCOLOGY (2018)
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
Davide Melisi et al.
BRITISH JOURNAL OF CANCER (2018)
Therapeutic strategies to target RAS-mutant cancers
Meagan B. Ryan et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
The bacterial Ras/Rap1 site-specific endopeptidase RRSP cleaves Ras through an atypical mechanism to disrupt Ras-ERK signaling
Marco Biancucci et al.
SCIENCE SIGNALING (2018)
LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer
Eliza Vakana et al.
ONCOTARGET (2017)
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
Matthew A. Coelho et al.
IMMUNITY (2017)
Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer The SELECT-1 Randomized Clinical Trial
Pasi A. Janne et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
Synthetic lethality screens point the way to new cancer drug targets (vol 16, pg 589, 2017)
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2017)
Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinoma
Arvin M. Gouw et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
AACR Project GENIE: Powering Precision Medicine through an International Consortium
Fabrice Andre et al.
CANCER DISCOVERY (2017)
The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
Edmund Poon et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
TAK-ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapy
Raffaela Santoro et al.
DRUG RESISTANCE UPDATES (2017)
KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma
Nan Chen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy
Christina H. Eng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression
Tikvah K. Hayes et al.
CANCER CELL (2016)
NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer
Iok In Christine Chio et al.
CELL (2016)
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
Peter J. R. Ebert et al.
IMMUNITY (2016)
Lung Cancer Subtypes Generate Unique Immune Responses
Stephanie E. Busch et al.
JOURNAL OF IMMUNOLOGY (2016)
XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer
Jimi Kim et al.
NATURE (2016)
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Ying-Nan P. Chen et al.
NATURE (2016)
A combinatorial strategy for treating KRAS-mutant lung cancer
Eusebio Manchado et al.
NATURE (2016)
Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers
Jared R. Mayers et al.
SCIENCE (2016)
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Piro Lito et al.
SCIENCE (2016)
CXCR2 signaling regulates KRAS(G12D)-induced autocrine growth of pancreatic cancer
Abhilasha Purohit et al.
ONCOTARGET (2016)
Fatty Acid Oxidation Mediated by Acyl-CoA Synthetase Long Chain 3 Is Required for Mutant KRAS Lung Tumorigenesis
Mahesh S. Padanad et al.
CELL REPORTS (2016)
Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells
Stephanie Zdanov et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Inhibition of RAF lsoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
Sheng-Bin Peng et al.
CANCER CELL (2015)
Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer
Shintaro Takeuchi et al.
CANCER RESEARCH (2015)
RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?
Julian Downward
CLINICAL CANCER RESEARCH (2015)
Cutting Edge: Identification of Autoreactive CD4(+) and CD8(+) T Cell Subsets Resistant to PD-1 Pathway Blockade
Kristen E. Pauken et al.
JOURNAL OF IMMUNOLOGY (2015)
Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against BRAF or RAS Mutant Tumor Cells
James R. Henry et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
RAF inhibitors that evade paradoxical MAPK pathway activation
Chao Zhang et al.
NATURE (2015)
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
Luping Lin et al.
NATURE GENETICS (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH
Jihye Yun et al.
SCIENCE (2015)
Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities
Ferdinandos Skoulidis et al.
CANCER DISCOVERY (2015)
Mutant KRAS-Induced Expression of ICAM-1 in Pancreatic Acinar Cells Causes Attraction of Macrophages to Expedite the Formation of Precancerous Lesions
Geou-Yarh Liou et al.
CANCER DISCOVERY (2015)
Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer
Avnish Kapoor et al.
CELL (2014)
KRAS and YAP1 Converge to Regulate EMT and Tumor Survival
Diane D. Shao et al.
CELL (2014)
Pancreatic Cancer: Systemic Combination Therapies for a Heterogeneous Disease
Davide Melisi et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
Jeffrey R. Infante et al.
EUROPEAN JOURNAL OF CANCER (2014)
Regulation of F-18-FDG Accumulation in Colorectal Cancer Cells with Mutated KRAS
Masayoshi Iwamoto et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function
Andrea Viale et al.
NATURE (2014)
Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library
Hiroko Koike-Yusa et al.
NATURE BIOTECHNOLOGY (2014)
Drugging the undruggable RAS: Mission Possible?
Adrienne D. Cox et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma
Brian M. Wolpin et al.
ONCOLOGIST (2014)
mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1
Anthony C. Faber et al.
CANCER DISCOVERY (2014)
Autophagy Is Critical for Pancreatic Tumor Growth and Progression in Tumors with p53 Alterations
Annan Yang et al.
CANCER DISCOVERY (2014)
Inhibition of KRAS-Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit
Zehua Zhu et al.
CANCER DISCOVERY (2014)
Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models
Ryan B. Corcoran et al.
CANCER CELL (2013)
Mice That Express Human Interleukin-8 Have Increased Mobilization of Immature Myeloid Cells, Which Exacerbates Inflammation and Accelerates Colon Carcinogenesis
Samuel Asfaha et al.
GASTROENTEROLOGY (2013)
Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis
Jessie Yanxiang Guo et al.
GENES & DEVELOPMENT (2013)
Loss of the Transcription Factor GLI1 Identifies a Signaling Network in the Tumor Microenvironment Mediating KRAS Oncogene-induced Transformation
Lisa D. Mills et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells
Cosimo Commisso et al.
NATURE (2013)
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Jonathan M. Ostrem et al.
NATURE (2013)
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
Jaekyoung Son et al.
NATURE (2013)
Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling
Gunther Zimmermann et al.
NATURE (2013)
Tumor adaptation and resistance to RAF inhibitors
Piro Lito et al.
NATURE MEDICINE (2013)
Coordinate Direct Input of Both KRAS and IGF1 Receptor to Activation of PI3 Kinase in KRAS-Mutant Lung Cancer
Miriam Molina-Arcas et al.
CANCER DISCOVERY (2013)
Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
Erick J. Morris et al.
CANCER DISCOVERY (2013)
Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy
Anna Tamburrino et al.
FRONTIERS IN PHARMACOLOGY (2013)
Oncogenic Kras-Induced GM-CSF Production Promotes the Development of Pancreatic Neoplasia
Yuliya Pylayeva-Gupta et al.
CANCER CELL (2012)
TAK1 Inhibition Promotes Apoptosis in KRAS-Dependent Colon Cancers
Anurag Singh et al.
CELL (2012)
The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer
Madhu S. Kumar et al.
CELL (2012)
Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism
Haoqiang Ying et al.
CELL (2012)
The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
Toshio Shimizu et al.
CLINICAL CANCER RESEARCH (2012)
Relationship between 18F-Fluorodeoxyglucose Accumulation and KRAS/BRAF Mutations in Colorectal Cancer
Kenji Kawada et al.
CLINICAL CANCER RESEARCH (2012)
Pancreatic Cancer: Between Bench and Bedside
Davide Melisi et al.
CURRENT DRUG TARGETS (2012)
NF-κB as a target for pancreatic cancer therapy
Carmine Carbone et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
Hippo Signaling Regulates Pancreas Development through Inactivation of Yap
Nicholas M. George et al.
MOLECULAR AND CELLULAR BIOLOGY (2012)
Systematic identification of genomic markers of drug sensitivity in cancer cells
Mathew J. Garnett et al.
NATURE (2012)
Origins of tumor-associated macrophages and neutrophils
Virna Cortez-Retamozo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
Eric A. Collisson et al.
CANCER DISCOVERY (2012)
Overexpression of CXCL5 Is Associated With Poor Survival in Patients With Pancreatic Cancer
Aihua Li et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
Exploiting Cancer Cell Vulnerabilities to Develop a Combination Therapy for Ras-Driven Tumors
Thomas De Raedt et al.
CANCER CELL (2011)
Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer
Marina Lesina et al.
CANCER CELL (2011)
STK33 Kinase Activity Is Nonessential in KRAS-Dependent Cancer Cells
Carol Babij et al.
CANCER RESEARCH (2011)
Blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathways by statins reduces the expression of bFGF, HGF, and TGF-β as angiogenic factors in mouse osteosarcoma
Masanobu Tsubaki et al.
CYTOKINE (2011)
Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer
Lucia De Monte et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Modulation of Pancreatic Cancer Chemoresistance by Inhibition of TAK1
Davide Melisi et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma
Marta Puyol et al.
CANCER CELL (2010)
Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models
Silvestre Vicent et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells
Y. Wang et al.
ONCOGENE (2010)
Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity
Frank Weinberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Autophagy and Metabolism
Joshua D. Rabinowitz et al.
SCIENCE (2010)
A Gene Expression Signature Associated with K-Ras Addiction Reveals Regulators of EMT and Tumor Cell Survival
Anurag Singh et al.
CANCER CELL (2009)
ELR plus CXC chemokines and oncogenic Ras-mediated tumorigenesis
Kevin M. O'Hayer et al.
CARCINOGENESIS (2009)
Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice
Angelica M. Santos et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
NF-κB: A Key Player in Lung Cancer
[Anonymous]
CELL (2009)
Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells
Jihye Yun et al.
SCIENCE (2009)
Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma
Etienne Meylan et al.
NATURE (2009)
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers
Alex A. Adjei et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells
Zhenyu Ji et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
NF-κB as a target for cancer therapy
Davide Melisi et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2007)
The pancreatic stellate cell: a star on the rise in pancreatic diseases
M. Bishr Omary et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
RaIB GTPase-mediated activation of the IκB family kinase TBK1 couples innate immune signaling to tumor cell survival
Yuchen Chien et al.
CELL (2006)
K-ras activation generates an inflammatory response in lung tumors
H Ji et al.
ONCOGENE (2006)
Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer
Sergei Kusmartsev et al.
CANCER AND METASTASIS REVIEWS (2006)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
The concept of synthetic lethality in the context of anticancer therapy
WG Kaelin
NATURE REVIEWS CANCER (2005)
Distinct requirements for Ras oncogenesis in human versus mouse cells
NM Hamad et al.
GENES & DEVELOPMENT (2002)
Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer
B Almand et al.
JOURNAL OF IMMUNOLOGY (2001)
Share Paper
